Objective: Progressive multifocal leukoencephalopathy (PML) is a severe complication of natalizumab therapy in patients with multiple sclerosis (MS), which is often accompanied by an immune reconstitution inflammatory syndrome (IRIS) after removal of the drug. We describe a patient with MS who presented with simultaneous PML-IRIS 2 months after stopping natalizumab for other reasons.
Three months after SO, he answered in two-word phrases and could take a few steps. MRI showed a decrease in the size of the PML lesions and absence of mass effect but also atrophy and a faint rim of enhancement in the left frontal lobe.
Three months later, he could walk unassisted and care for most of his daily activities. He still had expressive aphasia, planning difficulties, left-sided neglect, and a bilateral cerebellar syndrome. MRI 6 months after SO showed further atrophy at the site of the PML lesions. There was limited residual contrast en-hancement in the left frontal lobe, but new enhancement in the cerebellar lesions, indicating ongoing IRIS (figure, G-I).
He continued to improve, and MRI performed 3 months later showed resolution of enhancement and marked atrophy (figure, J-L). One year after onset, he spoke in short sentences and had a residual cerebellar syndrome and a minimal rightsided pyramidal syndrome. No new lesions were seen.
We used proton magnetic resonance spectroscopy ( 1 H-MRS) 3, 6, 9, and 15 months after SO to measure the concentration of N-acetyl-L-aspartate (NAA), a neuronal marker, choline (Cho), a component of cell membranes, myoinositol (mI), a glial marker associated with inflammation, and LIP1 and LIP2, markers of anaerobic metabolism, within PML lesions. Creatine (Cr) is a measure of basal metabolism, and all values are expressed as ratios. There was a decline in the NAA/Cr ratio until 9 months after SO, consistent with neuronal and axonal damage, and an increase at the last time point in the left frontal and cerebellar lesions. The Cho/Cr ratio showed a continuous decline consistent with decreased turnover in cell membranes. mI/Cr, LIP1/ Cr, and LIP2/Cr ratios increased in both lesions between 3 and 6 months after SO, concomitant with new enhancement in the cerebellum. When enhancement subsided 9 months after SO, the LIP2/Cr ratio remained elevated in both lesions, whereas the mI/Cr ratio remained elevated in the frontal lesion and the LIP1/Cr ratio continued to rise in the cerebellar lesion. Fifteen months after onset, the mI/Cr ratio decreased in the frontal lesion but increased again in the cerebellar lesion, whereas the lipid/Cr ratios decreased in both. JCV-specific T-cell responses were detected at the same time points in his blood. Although the CD4 ϩ T-lymphocyte response remained low, the CD8 ϩ T-lymphocyte response became robust over time.
DISCUSSION
This case illustrates that PML can develop even after discontinuation of natalizumab and occur simultaneously with IRIS. Simultaneous PML-IRIS had been mainly restricted to patients with AIDS starting HIV treatment. 2 Because natalizumab should be fully cleared from the circulation after approximately 2 months (5 half-lives), 3 it is likely that PML started to develop in our patient while the medication was still active. However, it only became clinically apparent when the effect of the medication wore off, allowing the return of lymphocytes back into the brain parenchyma, causing IRIS. This represents a challenge, because neurologic dysfunction and white matter lesions occurring after natalizumab interruption may be caused by MS exacerbations. 4 In addition, our patient was hospitalized with ethanol intoxication before the development of frank cerebellar symptoms, and the cognitive dysfunction caused by PML may have been compounded by ethanol.
Interestingly, this patient did not experience a relapse of MS over a 20-month period after PML onset. Indeed, 21% of patients with MS experience a relapse of MS during natalizumab interruption. 3 Although his PML lesions seemed extensive, he regained partial neurologic function and some of the abnormal MRI signal subsided after corticosteroid treatment, indicating that impairment was in part caused by reversible inflammation rather than permanent demyelination. Another explanation for his remarkable improvement could be remyelination, as seen in MS. However, this has not been previously described in the setting of PML, and the absence of histologic material precludes any definite conclusion.
There are no biomarkers to define IRIS, 2,5 and estimating PML outcome remains difficult. Survivors of PML are more likely to mount a JCV-specific cellular immune response than progressors, but this does not differentiate between patients with PML with or without IRIS. 6 This patient displayed a persistent T-cell response against JCV, which did not decrease once IRIS subsided and persisted regardless of corticosteroid use.
Lesions of survivors of PML have higher mI/Cr ratio peaks than those of progressors. 7 Of note, mI/ Cr, LIP1/Cr, and LIP2/Cr ratios seemed more sensitive than contrast enhancement as surrogate markers of inflammation in our patient. 8 Despite improvement, he developed marked brain atrophy, indicating the extent of demyelination caused by PML. 1 H-MRS may be an important marker in PML-IRIS, which could be used to monitor ongoing inflammation, help determine the need for corticosteroid administration, and anticipate continuing recovery when enhancement has already subsided.
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